Medicines360 Appoints Elizabeth Garner, M.D., M.P.H. to Board of Directors 

HRA Pharma logo

SAN FRANCISCO – May 12, 2022 – Medicines360, the mission-driven nonprofit women’s health pharmaceutical organization, has appointed Elizabeth Garner MD, MPH, as a member of its Board of Directors, effective immediately. With over a decade of pharmaceutical development experience, Dr. Garner brings expansive knowledge in regulatory and clinical affairs, and a deep commitment to increasing […]

Medicines360, Population Services International, and Society for Family Health Announce Launch of Avibela® Hormonal Intrauterine Device in Nigeria

Medicines 360 logo

Improving Access to Modern Contraception for Women in Nigeria  SAN FRANCISCO, WASHINGTON and ABUJA– March 22, 2022– Medicines360, Population Services International (PSI), and Society for Family Health (SFH) announced the launch of Avibela (levonorgestrel-releasing intrauterine system) 52 mg in Nigeria. Nigerian women and girls’ contraceptive options have historically been limited. The introduction of Avibela provides […]

Medicines360 Announces Price Subsidy of its Hormonal IUD Avibela to Expand Access to Contraception

Medicines 360 logo

In August 2021 – Medicines360, the mission-driven nonprofit Women’s Health pharmaceutical organization announced a price subsidy to expand contraceptive access for millions of women in some of the world’s poorest countries. When purchased from its subsidiary, Impact RH360, Avibela will be offered at the price of $9.50 through international procurement groups. “We believe that women […]

Medicines360 and the Population Council Pursue Agreement to Develop Product to Prevent HIV and Unintended Pregnancy for Worldwide Distribution

Medicines 360 logo

SAN FRANCISCO and NEW YORK, N.Y.: Medicines360, a mission-driven nonprofit women’s health pharmaceutical organization, and the Population Council, a global nonprofit research organization, have entered into a Memorandum of Understanding to develop a dual prevention pill (DPP) product to prevent both pregnancy and HIV in a single tablet – for global distribution. The organizations intend […]

Medicines360, MSI Reproductive Choices and MSK Announce Launch of Avibela® Hormonal Intrauterine Device in Kenya

Medicines 360 logo

Product Expands Access to High-Quality Contraception for Women in Africa SAN FRANCISCO and LONDON and NAIROBI– August 2, 2021 – Medicines360, MSI Reproductive Choices (MSI) and Marie Stopes Kenya (MSK) today announced the launch of AVIBELA (levonorgestrel-releasing intrauterine system) 52 mg in Kenya. This is the third launch of Medicines360’s hormonal intrauterine device (IUD) in […]

Medicines360 Appoints Tina Raine-Bennett, MD, MPH, FACOG, as Chief Executive Officer

Medicines 360 logo

Dr. Raine-Bennett brings passionate expertise in improving health outcomes for women SAN FRANCISCO – July 6, 2021 – Medicines360, a global nonprofit women’s health pharmaceutical organization, has appointed Tina Raine-Bennett, MD, MPH, FACOG, Chief Executive Officer (CEO), effective immediately, following a broad national search. With over 30 years of experience, Dr. Raine-Bennett has an extensive […]

Medicines360 Applauds Introduction of Federal Legislation to Support Nonprofit Pharmaceutical Organizations

Medicines 360 logo

For Immediate Release: June 25, 2021 SAN FRANCISCO – Today, Senator Jacky Rosen (D-NV) introduced the Expanding Access to Affordable Prescription Drugs and Medical Devices Act, a bill designed to support nonprofit pharmaceutical organizations in their efforts to sustainably increase access to affordable medicines for Americans. As the longest-standing nonprofit pharmaceutical organization serving the U.S. market, […]

Medicines360 and HRA Partner to Enhance Availability of Emergency Contraceptive ella® in the U.S.

Medicines 360 logo

SAN FRANCISCO and MORRISTOWN, N.J.: Medicines360, a mission-driven nonprofit women’s health pharmaceutical organization, and HRA Pharma, a global consumer healthcare company, announced today that the two organizations are partnering to support U.S. publicly funded family planning clinics’ access to prescription emergency contraceptive ulipristal acetate (UPA), commonly known in the U.S. as ella®. HRA Pharma first […]